Caisse de depot et placement du Quebec Buys Shares of 152,908 Medpace Holdings, Inc. $MEDP

Caisse de depot et placement du Quebec purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 152,908 shares of the company’s stock, valued at approximately $80,979,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Johnson Financial Group Inc. purchased a new stake in shares of Medpace during the second quarter valued at $27,000. Elyxium Wealth LLC purchased a new position in Medpace in the 4th quarter worth about $30,000. Jones Financial Companies Lllp purchased a new position in Medpace in the 2nd quarter worth about $30,000. Allied Private Wealth LLC bought a new position in Medpace during the 2nd quarter valued at about $31,000. Finally, Kilter Group LLC bought a new position in Medpace during the 2nd quarter valued at about $31,000. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 27,174 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the sale, the chief executive officer directly owned 561,195 shares of the company’s stock, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 129,963 shares of company stock valued at $79,364,624 over the last three months. Insiders own 20.50% of the company’s stock.

Medpace Stock Down 1.2%

NASDAQ MEDP opened at $611.57 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm has a market capitalization of $17.07 billion, a P/E ratio of 35.85, a PEG ratio of 2.76 and a beta of 1.15. The company has a 50-day moving average price of $562.52 and a 200-day moving average price of $493.80.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of research analyst reports. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Finally, Robert W. Baird increased their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.